Sage Therapeutics, Inc. (SAGE)
US — Healthcare Sector
Automate Your Wheel Strategy on SAGE
With Tiblio's Option Bot, you can configure your own wheel strategy including SAGE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SAGE
- Rev/Share 0.7663
- Book/Share 6.6257
- PB 1.3916
- Debt/Equity 0.0289
- CurrentRatio 9.1301
- ROIC -0.9062
- MktCap 577377606.0
- FreeCF/Share -5.0291
- PFCF -1.856
- PE -1.6093
- Debt/Assets 0.0252
- DivYield 0
- ROE -0.6899
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | SAGE | BofA Securities | -- | Underperform | -- | $5 | March 11, 2025 |
| Resumed | SAGE | Raymond James | -- | Market Perform | -- | -- | Oct. 10, 2024 |
| Downgrade | SAGE | RBC Capital Mkts | Outperform | Sector Perform | $10 | $4 | Oct. 4, 2024 |
News
Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Shareholders to Inquire about Securities Investigation
SAGE
Published: February 11, 2025 by: Accesswire
Sentiment: Neutral
Published: February 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE.
Read More
About Sage Therapeutics, Inc. (SAGE)
- IPO Date 2014-07-18
- Website https://www.sagerx.com
- Industry Biotechnology
- CEO Mr. Barry E. Greene
- Employees 353
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.